Next Generation Tissue Biomarkers Market Report Scope & Overview:

The Next Generation Tissue Biomarkers Market was valued at USD 3.25 Billion in 2025 and is expected to reach USD 6.89 Billion by 2035, growing at a CAGR of 7.80% from 2026-2035.

Next generation tissue biomarkers are molecular, genomic, proteomic, and spatial signatures identified directly within formalin-fixed or fresh-frozen tissue samples, used to characterize disease biology, guide treatment selection, and monitor therapy response with greater precision than conventional single-marker immunohistochemistry. Adoption is accelerating as oncology drug development relies on companion diagnostics and multi-marker profiling to identify patients most likely to respond to targeted and immuno-oncology therapies. Advances in spatial biology platforms, which preserve tissue architecture while profiling many biomarkers simultaneously, are expanding what pathology laboratories can learn from a single tissue section. Growth is concentrated in large reference laboratories and academic medical centers with the infrastructure to run sequencing and spatial profiling workflows, while broader community hospital adoption remains an earlier-stage opportunity.

⮞On June 12, 2026, Roche received FDA approval for its VENTANA PTEN (SP218) RxDx Assay, the first immunohistochemistry companion diagnostic approved to identify PTEN protein loss in prostate adenocarcinoma tissue, supporting patient selection for capivasertib.

U.S. Next Generation Tissue Biomarkers Market Outlook:

The U.S. Next Generation Tissue Biomarkers Market was valued at USD 1.29 Billion in 2025 and is expected to reach USD 2.81 Billion by 2035, growing at a CAGR of 8.10% from 2026-2035.

Demand across the United States is supported by a dense concentration of academic medical centers and large reference laboratories capable of running comprehensive genomic profiling and spatial biology workflows at scale. Centers for Medicare and Medicaid Services (CMS) coverage of FDA-approved tumor profiling panels gives laboratories a defined payment pathway, while leading diagnostics and life sciences companies headquartered in the country continue to direct new product launches and regulatory submissions toward the national market first. National laboratory networks are also digitizing anatomic pathology at scale, placing AI-assisted biomarker quantification into routine workflows sooner than in most other markets.

⮞On February 23, 2026, Labcorp expanded its collaboration with PathAI to deploy the FDA-cleared AISight Dx digital pathology platform across its anatomic pathology laboratories and hospital collaborations nationwide.

By Product, Reagents and Assays Dominates the Next Generation Tissue Biomarkers Market and Software and AI Grows Fastest

Reagents and assays hold the dominant product share, reflecting their position as the recurring, consumable component of every tissue biomarker workflow regardless of which instrument platform a laboratory has adopted. Laboratories running high test volumes repeatedly purchase reagent kits, staining panels, and sequencing consumables, generating a steady revenue stream for suppliers that is far larger than the one-time instrument purchase itself. This recurring consumable demand also gives established reagent suppliers a durable relationship with laboratory customers that newer entrants focused only on instrumentation find difficult to displace.

Software and AI tools are the fastest-growing product category, as digital pathology platforms increasingly bundle artificial intelligence algorithms for image quality control, biomarker quantification, and workflow triage alongside scanning hardware. Laboratories adopting these tools report meaningful reductions in manual review time and more consistent biomarker scoring across pathologists, which is accelerating purchasing interest beyond the largest academic centers that first validated the technology. As more vendors secure regulatory clearance for AI-assisted pathology software, adoption is expected to broaden into community laboratory settings.

⮞On March 25, 2026, Bio-Techne expanded its COMET spatial biology portfolio with new SPYRE Focus Panels for stroma and vessel profiling and SPYRE Amplification Kits designed to improve detection of low-abundance tissue targets.

By Biomarker Type, Genomic Biomarkers Dominates the Next Generation Tissue Biomarkers Market and Metabolomic Biomarkers Grows Fastest

Genomic biomarkers hold the dominant biomarker-type share, supported by the maturity of next-generation sequencing and polymerase chain reaction-based tissue testing relative to newer biomarker classes. Oncology drug labels increasingly specify genomic alterations, such as specific gene fusions or mutations, as eligibility criteria for targeted therapy, giving genomic tissue testing the broadest and most established clinical adoption among next-generation biomarker categories. Reference laboratories have correspondingly built the largest share of their testing menus and validated clinical workflows around genomic biomarker detection.

Metabolomic biomarkers are the fastest-growing biomarker type, as researchers increasingly recognize that metabolic reprogramming within tumor tissue carries diagnostic and prognostic information not fully captured by genomic or proteomic profiling alone. Mass spectrometry-based tissue metabolomics platforms are moving from specialized research laboratories toward early clinical validation studies, particularly in oncology and neurology applications where metabolic signatures can distinguish aggressive from indolent disease. As analytical platforms mature and standardize, metabolomic tissue testing is expected to expand beyond its current research-focused base.

⮞On May 20, 2026, Discovery Life Sciences launched Luminos Comprehensive, a 164-gene pan-tumor genomic profiling panel validated on FFPE tissue as an IVDR-compliant test for oncology trials at European sites.

By Technology, Next-Generation Sequencing Dominates the Next Generation Tissue Biomarkers Market and Spatial Biology Platforms Grows Fastest

Next-generation sequencing holds the dominant technology share, reflecting its established regulatory pathway, broad clinical validation, and ability to detect a wide range of genomic alterations from a single tissue sample in one sequencing run rather than through several narrower assays. Reference laboratories and academic medical centers have invested heavily in next-generation sequencing infrastructure over the past decade, and this installed base gives the technology a durable advantage as pharmaceutical sponsors continue to specify sequencing-based companion diagnostics for new oncology drug approvals across multiple indications.

Spatial biology platforms are the fastest-growing technology, as researchers and pathologists increasingly value the ability to map biomarker expression while preserving the original spatial architecture of a tissue sample, information that dissociated single-cell and bulk sequencing methods cannot capture. Growing cross-platform compatibility between spatial imaging systems and downstream sequencing and proteomic validation tools is lowering the adoption barrier for laboratories new to spatial profiling, supporting faster growth than conventional sequencing-only approaches as more vendors secure regulatory clearance for clinical-grade spatial platforms.

⮞On April 17, 2026, Bruker Spatial Biology showcased new cross-platform spatial biology workflows linking its GeoMx, CosMx, and CellScape systems at the AACR Annual Meeting.

By Application, Oncology Dominates the Next Generation Tissue Biomarkers Market and Companion Diagnostics Grows Fastest

Oncology accounts for the dominant application share, consistent with cancer's position as the disease area where tissue biomarker testing is most clinically established and most closely tied to specific, label-mandated treatment decisions. The sheer volume of cancer diagnoses worldwide, combined with an expanding menu of targeted and immuno-oncology therapies requiring biomarker-based patient selection, gives oncology testing a scale advantage over other application areas such as neurology or cardiology, where tissue biomarker use remains comparatively early stage and far less standardized across laboratories.

Companion diagnostics are the fastest-growing application, as pharmaceutical sponsors increasingly co-develop a specific biomarker test alongside a new targeted therapy to satisfy regulatory requirements for patient selection ahead of commercial launch. Recent companion diagnostic approvals covering multiple drug indications on a single comprehensive genomic profiling panel are reducing the need for sequential single-biomarker testing, a shift that is accelerating reference laboratory adoption of broad panels over narrower, drug-specific assays that once dominated this testing category entirely before multiplexed panels became the accepted clinical standard.

⮞On February 11, 2026, Agilent Technologies received FDA approval for PD-L1 IHC 22C3 pharmDx as a companion diagnostic for first-line KEYTRUDA treatment in epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, its seventh FDA-approved indication for use with the therapy.

Regional Analysis:

North America Next Generation Tissue Biomarkers Market Insights

North America is the largest regional market, with an estimated 45.00% share in 2025, anchored by the United States' dense concentration of academic medical centers, reference laboratories, and pharmaceutical sponsors driving companion diagnostic development. Large national laboratory networks are digitizing anatomic pathology and consolidating specialist testing, while the region's mature regulatory pathway gives diagnostics companies a comparatively fast and predictable route to market for new tissue biomarker tests relative to most other regions.

Canada contributes a smaller but steady share of regional demand, with provincial cancer agencies gradually adding selected next-generation sequencing and companion diagnostic panels to publicly funded test menus as supporting clinical evidence accumulates across multiple provincial review cycles. Continued growth in oncology drug approvals requiring biomarker-based patient selection is reinforcing demand for comprehensive tissue profiling across the region, while leading diagnostics companies headquartered in the United States continue to prioritize national regulatory submissions ahead of international filings in most product categories, giving the region earlier access to newly cleared biomarker tests than most international markets.

⮞On March 23, 2026, Abbott completed its acquisition of Exact Sciences, bringing the tissue-based Oncotype DX breast cancer treatment-decision test into its diagnostics portfolio as a wholly owned subsidiary.

Asia Pacific Next Generation Tissue Biomarkers Market Insights

Asia Pacific recorded the fastest regional growth, with a CAGR of approximately 16.50% from 2026-2035, driven by rising cancer incidence, expanding reference laboratory capacity, and growing government investment in precision oncology infrastructure across China, Japan, and South Korea. China's expanding network of hospitals capable of performing comprehensive genomic profiling is widening the addressable patient population for next-generation tissue biomarker testing faster than in most established markets, aided by growing local reagent and instrument manufacturing capability that is gradually narrowing its technology gap with Western suppliers.

Japan’s established pathology framework and South Korea’s expanding genomic testing capability are both contributing to regional demand, as local laboratories are increasingly partnering with global diagnostics companies to access sequencing and spatial biology technology that they cannot yet affordably build themselves. India’s growing network of private hospitals is slowly rolling out full tissue biomarker panels for patients able to pay for advanced testing. Regional distribution partnerships between global and local diagnostics companies continue to expand access to test menus across the wider region.

⮞On April 18, 2026, 10x Genomics introduced its Atera whole-transcriptome in situ spatial platform, with Korea-based Macrogen and its subsidiary Psomagen committing to deploy multiple instruments as the first global service provider.

Europe Next Generation Tissue Biomarkers Market Insights

Europe is the second-largest regional market, with an estimated 26.00% share in 2025, supported by Germany's large diagnostic laboratory base and the region's generally coordinated national health technology assessment processes for new companion diagnostic panels. The May 2026 IVDR deadline for Class C devices, the category covering companion diagnostics, has pushed manufacturers to certify their tissue assays under the new framework, narrowing the menu of tests laboratories can run while raising confidence in those that remain ahead of procurement negotiations with national and regional health authorities.

The United Kingdom and France both maintain substantial pathology laboratory networks and are gradually adding selected next-generation biomarker panels to national test directories as supporting clinical evidence passes through assessment bodies that can take several years to complete a full review. Regional diagnostics companies continue to invest in companion diagnostic development and distribution partnerships, an area where several European life sciences companies maintain long-standing laboratory instrumentation and reagent manufacturing expertise built up over decades of continuous research investment and close academic collaboration.

⮞On June 11, 2026, Roche received IVDR approval for label expansions of its VENTANA MMR RxDx Panel, making the immunohistochemistry companion diagnostic available across five cancer types and six indications in IVDR-regulated countries.

MEA & Latin America Next Generation Tissue Biomarkers Market Insights

The Middle East and Africa is a smaller but steadily growing market for next-generation tissue biomarkers, with an estimated 4.00% share in 2025, led by Saudi Arabia and the United Arab Emirates as both countries invest in expanding specialized cancer center capacity as part of broader healthcare infrastructure modernization programs. South Africa's more established private laboratory network continues to introduce selected companion diagnostic panels, though adoption across the wider region remains concentrated among a small number of advanced tertiary cancer centers.

Latin America represented a smaller 3.00% share in 2025, with Brazil as the region's largest national market given its sizable cancer patient population and growing private laboratory sector. Mexico's expanding private healthcare network is gradually introducing comprehensive genomic profiling panels for patients able to afford advanced testing, while broader adoption across the region continues to be shaped by out-of-pocket payment requirements and the comparatively higher cost of next-generation biomarker panels relative to conventional single-marker testing.

⮞On July 15, 2026, Grupo Fleury took over commercial distribution and logistics of Foundation Medicine's FoundationOne precision oncology tests in Brazil through its Fleury Genômica platform.

Market Dynamics:

Growth Drivers: Expanding companion diagnostic requirements and reimbursement coverage sustain demand

The growing requirement for biomarker-based patient selection alongside new targeted and immuno-oncology drug approvals is a primary driver of next-generation tissue biomarker demand. Pharmaceutical sponsors increasingly co-develop comprehensive genomic profiling panels capable of supporting multiple companion diagnostic indications on a single test, reducing the clinical and commercial burden of running several narrower single-biomarker assays and reinforcing demand for broad testing platforms over conventional single-marker alternatives that once defined this testing category across most major indications, reshaping how laboratories plan their test menus and capital investment priorities for the years ahead.

A second driver is expanding reimbursement coverage for multi-gene tumor profiling panels across major markets, which is lowering the out-of-pocket cost barrier that previously limited testing to the largest academic cancer centers. Recent coverage decisions extending reimbursement to comprehensive genomic profiling tests are giving community laboratories and smaller hospital systems a stronger financial case to bring next-generation tissue biomarker testing in-house rather than referring samples to outside reference laboratories for every patient sample they collect, shortening turnaround times for treating physicians and their patients.

⮞On January 20, 2026, Illumina secured Centers for Medicare and Medicaid Services (CMS) reimbursement for its TruSight Oncology Comprehensive genomic profiling test, effective January 1, 2026.

Restraints: Standardization gaps and long validation timelines constrain broader adoption

A lack of standardization across next-generation tissue biomarker platforms remains a significant restraint, as different sequencing, spatial biology, and digital pathology systems can produce varying results from the same tissue sample, complicating efforts to compare data across laboratories or validate a test for broad clinical use. This variability slows regulatory approval timelines and makes some pathologists cautious about fully replacing established single-marker testing methods with newer multi-marker platforms across their routine daily caseload, particularly in smaller laboratories with limited bioinformatics staffing.

A second restraint is the lengthy clinical validation and regulatory review timeline required for new tissue biomarker tests, particularly companion diagnostics tied to a specific therapeutic indication. Smaller diagnostics companies without the capital to sustain multi-year validation studies are particularly exposed to this timing risk relative to larger, more diversified competitors, limiting the pace at which innovative biomarker technologies reach routine clinical use across the broader laboratory market and its many smaller customers who depend on predictable product timelines to plan their own testing menu expansion.

Opportunities: Spatial biology expansion and emerging-market laboratory investment widen demand

Continued advancement of spatial biology platforms toward routine clinical use represents a meaningful opportunity, as diagnostics companies that secure regulatory clearance for spatially-resolved biomarker tests stand to capture demand from pathologists seeking richer tissue context than dissociated sequencing methods provide. Companies investing early in spatial biology clinical validation studies are positioned to establish reference workflows that later entrants will need to match once broader clinical adoption accelerates across pathology practice, particularly as pathology guidelines begin recognizing spatial testing as distinct from conventional sequencing.

A second opportunity lies in rising laboratory infrastructure investment across emerging markets in Asia Pacific, the Middle East, and Latin America, where governments and private hospital groups are expanding diagnostic testing capacity at a pace not seen in more mature regional markets. Diagnostics companies establishing early distribution and laboratory-training partnerships in these markets are positioned to capture growing test volumes as local laboratory accreditation and testing networks mature over the coming years, ahead of slower-moving competitors still focused mainly on established Western markets.

⮞On February 25, 2026, Bruker launched CellScape XR, a spatial proteomics platform designed to support development of diagnostic and prognostic tissue assays through high-throughput, quantitative spatial analysis.

Next Generation Tissue Biomarkers Market Key Players:

• Roche Diagnostics

• Agilent Technologies, Inc.

• Thermo Fisher Scientific Inc.

• Illumina, Inc.

• QIAGEN N.V.

• NeoGenomics, Inc.

• Bruker Spatial Biology

• Bio-Techne Corporation

• Leica Biosystems

• Foundation Medicine, Inc.

• Labcorp

• Quest Diagnostics Incorporated

• Bio-Rad Laboratories, Inc.

• PathAI, Inc.

• 10x Genomics, Inc.

• Caris Life Sciences, Inc.

• Tempus AI, Inc.

• Visiopharm A/S

Next Generation Tissue Biomarkers Market Report Scope: